Interactions between pharmacologic and nonpharmacologic antiarrhythmic therapy

American Journal of Cardiology

Volumn 78, Issue 4 A, 1996, Pages 61-66

  Greene, H Leon ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; AMIODARONE; ANTIARRHYTHMIC AGENT; BRETYLIUM; DIGITALIS; DISOPYRAMIDE; ENCAINIDE; FLECAINIDE; ISOPRENALINE; LIDOCAINE; MEXILETINE; MORACIZINE; PHENYTOIN; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; VERAPAMIL;

ANTIARRHYTHMIC ACTIVITY; CARDIOVERSION; CLINICAL TRIAL; CONFERENCE PAPER; DEFIBRILLATOR; DRUG EFFECT; DRUG SAFETY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PACING; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0029840203     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9149(96)00454-7     Document Type: Conference Paper

References (49)

1. Siebels J, Kuck K-H, CASH Investigators. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J 1994;127:1139-1144.
2. Connolly SJ, Gent M, Roberts RS, Dorian P, Green MS, Klein GJ, Mitchell LB, Sheldon RS, Roy D on behalf of the CIDS Co-Investigators. Canadian Implantable Defibrillator Study (CIDS): study design and organization. Am J Cardiol 1993;72(suppl):103F-108F.
3. The AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators (AVID) - rationale, design, and methods. Am J Cardiol 1995;75:470-475.
4. Thomas AC, Moser SA, Smutka ML, Wilson PA. Implantable defibrillation: eight years clinical experience. PACE 1988:11:2053-2058.
5. Echt DS, Armstrong K, Schmidt P, Oyer PE, Stinson EB, Winkle RA. Clinical experience, complications, and survival in 70 patients with the automatic implantable cardioverter/defibrillator. Circulation 1985;71:289-296.
6. Kelly PA, Cannom DS, Garan H, Mirabal GS, Harthorne JW, Hurvitz RJ, Vlahakes GJ, Jacobs ML, Ilvento JP, Buckley MJ, Ruskin JN. The automatic implantable cardioverter-defibrillator: efficacy, complications and survival in patients with malignant ventricular arrhythmias. J Am Coll Cardiol 1988;11:1278-1286.
7. Winkle RA, Mead RH, Ruder MA, Gaudiani VA, Smith NA, Buch WS, Schmidt P, Shipman T. Long-term outcome with the automatic implantable cardioverter-defibrillator. J Am Coll Cardiol 1989;13:1353-1361.
8. Kelly PA, Cannom DS, Garan H, Finkelstein D, McComb JM, Mirabal GS, Ilvento JP, Ruskin JN. Predictors of automatic implantable cardioverter defibrillator discharge for life-threatening ventricular arrhythmias. Am J Cardiol 1988;62:83-87.
9. Bardy GH, Troutman C, Poole JE, Kudenchuk PJ, Dolack GL, Johnson G, Hofer B. Clinical experience with a tiered-therapy, multiprogrammable antiarrhythmia device. Circulation 1992;85:1689-1698.
10. Sperry RE, Stambler BS, Cycan A, Wood MA, Kaye S, Ellenbogen KA. Has antiarrhythmic drug use declined in patients receiving implantable cardioverter defibrillators (ICDs)? (Abstr.) J Am Coll Cardiol 1993;21:155A.
11. Estes NAM, Haugh CJ, Wang PJ, Manolis AS. Antitachycardia pacing and low-energy cardioversion for ventricular tachycardia termination: a clinical perspective. Am Heart J 1994;127:1038-1046.
12. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
13. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-233.
14. Manz M, Jung W, Lüderitz B. Interactions between drugs and devices: experimental and clinical studies. Am Heart J 1994;127:978-984.
15. Huang SKS, de Guzman WLT, Chenarides JG, Okike NO, Vander Salm TJ. Effects of long-term amiodarone therapy on the defibrillation threshold and the rate of shocks of the implantable cardioverter-defibrillator. Am Heart J 1991;122:720-727.
16. Kou WH, Kirsh MM, Rolling SF, Stirling M, Kadish AH, De Buitleir M, Calkins H, Lewis RR, Morady F. Effect of antiarrhythmic drug therapy on the incidence of shocks in patients who receive an implantable cardioverter defibrillator after a single episode of sustained ventricular tachycardia/fibrillation. PACE 1991;14:1586-1592.
17. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am J Cardiol 1993;72:280-287.
18. Dolack GL, CASCADE Investigators. Clinical predictors of implantable cardioverter-defibrillator shocks (results of the CASCADE Trial). Am J Cardiol 1994;73:237-241.
19. Wisenberg G. Antiarrhythmics: potential for negative inotropic effects. Prim Cardiol 1986;12:102-114.
20. Ravid S, Podrid PJ, Lampert S, Lown B. Congestive heart failure induced by six of the newer antiarrhythmic drugs. J Am Coll Cardiol 1989;14:1326-1330.
21. Hodges M, Salerno DM, Granrud G, Flecainide-Quinidine Research Group. Flecainide versus quinidine: results of a multicenter trial. Am J Cardiol 1984:53(suppl);66B-71B.
22. Podrid PJ, Schoeneberger A, Lown B. Congestive heart failure caused by oral disopyramide. N Engl J Med 1980;302:614-617.
23. Gottlieb SS, Kukin ML, Medina N, Yushak M, Packer M. Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure. Circulation 1990;81:860-864.
24. Stein J, Podrid P, Lown B. Effects of oral mexiletine on left and right ventricular function. Am J Cardiol 1984;54:575-578.
25. Podrid PJ, Beau SL. Antiarrhythmic drug therapy for congestive heart failure with focus on moricizine. Am J Cardiol 1990;65(suppl):56D-64D.
26. Vanerio G, Maloney JD. Moricizine: pharmacodynamic, pharmacokinetic, and therapeutic profile of a new antiarrhythmic. Cleve Clin J Med 1992;59:79-86.
27. Pratt CM, Podrid PJ, Seals AA, Young JB, Hession M, Lampert S, Quiñones M, Lown B. Effects of Ethmozine (moricizine HCl) on ventricular function using echocardiographic, hemodynamic and radionuclide assessments. Am J Cardiol 1987;60(suppl):73F-78F.
28. Josephson MA, Ikeda N, Singh BN. Effects of flecainide on ventricular function: clinical and experimental correlations. Am J Cardiol 1984;53(suppl):94B-100B.
29. DiBianco R, Fletcher RD, Cohen AI, Gottdiener JS, Singh SN, Katz RJ, Bates HR, Sauerbrunn B. Treatment of frequent ventricular arrhythmia with encainide: assessment using serial ambulatory electrocardiograms, intracardiac electrophysiologic studies, treadmill exercise tests, and radionuclide cineangiographic studies. Circulation 1982;65:1134-1147.
30. Gottlieb SS, Kukin ML, Yushak M, Medina N, Packer M. Adverse hemodynamic and clinical effects of encainide in severe chronic heart failure. Ann Intern Med 1989;110:505-509.
31. Podrid PJ, Lown B. Propafenone: a new agent for ventricular arrhythmia. J Am Coll Cardiol 1984;4:117-125.
32. Podrid PJ, Cytryn R, Lown B. Propafenone: noninvasive evaluation of efficacy. Am J Cardiol 1984;54(suppl):53D-59D.
33. Trobaugh GB, Kudenchuk PJ, Greene HL, Tutt RC, Kingston E, Gorham JR, Gross BW, Graham EL, Sears GK, Werner JA. Effect of amiodarone on ventricular function as measured by gated radionuclide angiography. Am J Cardiol 1984;54:1263-1266.
34. Nicklas JM, Mickelson JK, Das SK, Morady F, Schork MA, Pitt B. Prospective, randomized, double-blind, placebo-controlled trial of low dose amiodarone in patients with severe heart failure and frequent ventricular ectopy. (Abstr.) Circulation 1988;78:II-27.
35. Middlekauff HR, Stevenson WG, Stevenson LW, Saxon LA. Antiarrhythmic drug therapy in 367 heart failure patients: class I drugs but not amiodarone are associated with increased sudden death risk. (Abstr.) J Am Coll Cardiol 1991;17:92A.
36. Mahmarian JJ, Verani MS, Hohmann T, Hill R, Thornton BC, Bolli R, Young JB, Roberts R, Pratt CM. The hemodynamic effects of sotalol and quinidine: analysis by use of rest and exercise gated radionuclide angiography. Circulation 1987;76:324-331.
37. Ruffy R. Pharmacological modulation of ventricular defibrillation. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia: WB Saunders, 1990:959-962.
38. Babbs CF. Effects of drugs on defibrillation threshold. In: Tacker WA Jr, ed. Defibrillation of the Heart: ICDs, AEDs, and Manual. St. Louis: Mosby, 1994:223-258.
39. Guarnieri T, Levine JH, Veltri EP, Griffith LSC, Watkins L Jr, Juanteguy J, Mower MM, Mirowski M. Success of chronic defibrillation and the role of antiarrhythmic drugs with the automatic implantable cardioverter/defibrillator. Am J Cardiol 1987;60:1061-1064.
40. Jung W, Manz M, Pfeiffer D, Tebbenjohanns J, Pizzulli L, Lüderitz B. Effects of antiarrhythmic drugs on epicardial defibrillation energy requirements and the rate of defibrillator discharges. PACE 1993;16:198-201.
41. Jung W, Manz M, Lüderitz B. Effects of antiarrhythmic drugs on defibrillation threshold in patients with the implantable cardioverter defibrillator. PACE 1992;15:645-648.
42. Khastgir T, Lattuca J, Aarons D, Murphy J, O'Mara V, Juanteguy J, Veltri EP. Ventricular pacing threshold and time to capture postdefibrillation in patients undergoing implantable cardioverter-defibrillator implantation. PACE 1991;14:768-772.
43. Dorian P, Fain ES, Davy J-M, Winkle RA. Effect of quinidine and bretylium on defibrillation energy requirements. Am Heart J 1986;112:19-25.
44. Marinchak RA, Friehling TD, Kline RA, Stohler J, Kowey PR. Effect of antiarrhythmic drugs on defibrillation threshold: case report of an adverse effect of mexiletine and review of the literature. PACE 1988;11:7-12.
45. Ujhelyi MR, O'Rangers EA, Kluger J, Fan C, Chow M. Defibrillation energy requirements during moricizine and moricizine-lidocaine therapy. J Cardiovasc Pharmacol 1992;20:932-939.
46. Fain ES, Dorian P, Davy J-M, Kates RE, Winkle RA. Effects of encainide and its metabolites on energy requirements for defibrillation. Circulation 1986;73:1334-1341.
47. Wang M, Dorian P. DL and D sotalol decrease defibrillation energy requirements. PACE 1989;12:1522-1529.
48. Frame LH. The effect of chronic oral and acute intravenous amiodarone administration on ventricular defibrillation threshold using implanted electrodes in dogs. PACE 1989;12:339-346.
49. Jung W, Manz M, Pizzulli L, Pfeiffer D, Lüderitz B. Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol 1992;70:1023-1027.